Survodutide

GLP-1 / MetabolicResearch Use Only

Also known as: BI 456906, GLP-1/glucagon dual agonist

Survodutide is an investigational GLP-1 and glucagon receptor dual agonist commonly referenced in metabolic and liver research literature. Studies describe its dual mechanism in the context of weight regulation and metabolic liver conditions. It is a subject of ongoing clinical investigation.

Typical range (research)

Research literature commonly references escalating weekly amounts studied across roughly the ~2–6 mg/week range in trials

Half-life

~5 days (reported)

Route

Subcutaneous (research)

Common use

Metabolic and liver-health research

Common vial sizes

10 mg

Storage

Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.

Stacking notes

Referenced in research as a single dual-agonist molecule; combining with other incretin agents is not standard in the literature.

Reported side effects

NauseaReduced appetiteGastrointestinal upsetVomiting (reported in trials)

Regulatory note: Investigational; not FDA-approved and not approved in Canada. Phase 3 trials ongoing. Research-grade material is not for human use.

Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.